ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
ResMed Inc. (NYSE: RMD, ASX: RMD) reported strong Q4 2024 results with year-over-year revenue growth of 9% to $1.2 billion. Key highlights include:
- Gross margin improved 350 bps to 58.5%
- Income from operations increased 38%
- Operating cash flow of $440 million
- Diluted EPS of $1.98; non-GAAP diluted EPS of $2.08
- Quarterly dividend increased 10% to $0.53 per share
For the full fiscal year 2024, ResMed achieved:
- Revenue growth of 11% to $4.7 billion
- Gross margin improvement of 90 bps to 56.7%
- Income from operations increase of 17%
- Operating cash flow of $1.4 billion
- Diluted EPS of $6.92; non-GAAP diluted EPS of $7.72
The company reported strong performance across all sectors, driven by high demand for its products and software solutions.
ResMed Inc. (NYSE: RMD, ASX: RMD) ha riportato risultati solidi per il quarto trimestre del 2024, con una crescita dei ricavi anno su anno del 9% raggiungendo $1,2 miliardi. I principali punti salienti includono:
- Margine lordo migliorato di 350 punti base al 58,5%
- Reddito operativo aumentato del 38%
- Flusso di cassa operativo di $440 milioni
- EPS diluiti di $1,98; EPS diluiti non-GAAP di $2,08
- Dividendo trimestrale aumentato del 10% a $0,53 per azione
Per l'intero anno fiscale 2024, ResMed ha raggiunto:
- Crescita dei ricavi dell'11% a $4,7 miliardi
- Miglioramento del margine lordo di 90 punti base al 56,7%
- Aumento del reddito operativo del 17%
- Flusso di cassa operativo di $1,4 miliardi
- EPS diluiti di $6,92; EPS diluiti non-GAAP di $7,72
La società ha riportato una forte performance in tutti i settori, sostenuta da un'elevata domanda per i suoi prodotti e soluzioni software.
ResMed Inc. (NYSE: RMD, ASX: RMD) reportó sólidos resultados del cuarto trimestre de 2024, con un crecimiento interanual de ingresos del 9%, alcanzando $1.2 mil millones. Los aspectos más destacados incluyen:
- Margen bruto mejorado en 350 puntos base al 58.5%
- Ingreso de operaciones incrementado en un 38%
- Flujo de caja operativo de $440 millones
- EPS diluidos de $1.98; EPS diluidos no-GAAP de $2.08
- Dividendo trimestral incrementado en un 10% a $0.53 por acción
Para el año fiscal completo 2024, ResMed logró:
- Crecimiento de ingresos del 11% a $4.7 mil millones
- Mejora del margen bruto de 90 puntos base al 56.7%
- Aumento del ingreso operativo del 17%
- Flujo de caja operativo de $1.4 mil millones
- EPS diluidos de $6.92; EPS diluidos no-GAAP de $7.72
La compañía reportó un sólido desempeño en todos los sectores, impulsado por una alta demanda de sus productos y soluciones de software.
ResMed Inc. (NYSE: RMD, ASX: RMD)는 2024년 4분기 실적을 발표하며 전년 대비 9%의 매출 성장률을 기록하여 12억 달러에 이르렀습니다. 주요 하이라이트는 다음과 같습니다:
- 총 마진이 350bps 개선되어 58.5%를 기록
- 운영 수익이 38% 증가
- 운영 현금 흐름 4억 4천만 달러
- 희석 주당순이익(EPS) 1.98달러; 비-GAAP 희석 EPS 2.08달러
- 분기 배당금 10% 증가하여 주당 0.53달러
2024 회계연도 전체에 대해 ResMed는:
- 매출이 11% 증가하여 47억 달러에 도달
- 총 마진이 90bps 개선되어 56.7% 기록
- 운영 수익이 17% 증가
- 운영 현금 흐름 14억 달러
- 희석 EPS 6.92달러; 비-GAAP 희석 EPS 7.72달러
회사는 모든 부문에서 강력한 성과를 보고했으며, 이는 자사 제품 및 소프트웨어 솔루션에 대한 높은 수요에 의해 주도되었습니다.
ResMed Inc. (NYSE: RMD, ASX: RMD) a annoncé de solides résultats pour le quatrième trimestre 2024, avec une croissance des revenus de 9 % par rapport à l'année précédente, atteignant 1,2 milliard de dollars. Les points saillants comprennent :
- Marge brute améliorée de 350 points de base à 58,5 %
- Résultat opérationnel en augmentation de 38 %
- Flux de trésorerie opérationnel de 440 millions de dollars
- BPA dilué de 1,98 $ ; BPA dilué non-GAAP de 2,08 $
- Dividende trimestriel augmenté de 10 % à 0,53 $ par action
Pour l'exercice fiscal complet 2024, ResMed a réalisé :
- Croissance des revenus de 11 % à 4,7 milliards de dollars
- Amélioration de la marge brute de 90 points de base à 56,7 %
- Augmentation du résultat opérationnel de 17 %
- Flux de trésorerie opérationnel de 1,4 milliard de dollars
- BPA dilué de 6,92 $ ; BPA dilué non-GAAP de 7,72 $
L'entreprise a rapporté de solides performances dans tous les secteurs, soutenues par une forte demande pour ses produits et solutions logicielles.
ResMed Inc. (NYSE: RMD, ASX: RMD) hat starke Ergebnisse für das 4. Quartal 2024 berichtet, mit einem Umsatzwachstum von 9% im Jahresvergleich auf 1,2 Milliarden Dollar. Zu den wichtigsten Punkten gehören:
- Bruttomarge um 350 Basispunkte auf 58,5% verbessert
- Betriebseinkommen um 38% gestiegen
- Operativer Cashflow von 440 Millionen Dollar
- Verwässerter Gewinn je Aktie (EPS) von 1,98 Dollar; nicht-GAAP verwässerter EPS von 2,08 Dollar
- Quartalsdividende um 10% auf 0,53 Dollar pro Aktie erhöht
Für das gesamte Geschäftsjahr 2024 erzielte ResMed:
- Umsatzwachstum von 11% auf 4,7 Milliarden Dollar
- Verbesserung der Bruttomarge um 90 Basispunkte auf 56,7%
- Anstieg des Betriebseinkommens um 17%
- Operativer Cashflow von 1,4 Milliarden Dollar
- Verwässerter EPS von 6,92 Dollar; nicht-GAAP verwässerter EPS von 7,72 Dollar
Das Unternehmen berichtete von einer starken Leistung in allen Bereichen, bedingt durch eine hohe Nachfrage nach seinen Produkten und Softwarelösungen.
- Revenue increased by 9% to $1.2 billion in Q4 2024
- Gross margin improved 350 bps to 58.5% in Q4 2024
- Income from operations increased 38% in Q4 2024
- Operating cash flow of $440 million in Q4 2024
- Full year 2024 revenue increased by 11% to $4.7 billion
- Full year 2024 operating cash flow of $1.4 billion
- Quarterly dividend increased 10% to $0.53 per share
- Strong growth across devices, masks, and software businesses
- Selling, general, and administrative expenses increased by 1% on a constant currency basis in Q4 2024
Insights
ResMed's Q4 and FY2024 results demonstrate robust performance across all business segments. The company reported impressive year-over-year growth, with revenue increasing
Notably, the company's focus on operational excellence and cost discipline has yielded significant improvements in profitability. Gross margin expanded by 350 basis points to
ResMed's strong cash flow generation is particularly impressive, with operating cash flow of
The company's position as a market leader in the underpenetrated sleep health and breathing disorders market presents significant growth opportunities. With nearly 2.5 billion people suffering from these disorders globally, ResMed is well-positioned to drive increased market penetration and accelerate growth across its businesses.
However, investors should be aware of potential challenges such as currency fluctuations and ongoing global supply chain issues that could impact future performance. Overall, ResMed's strong financial results and strategic positioning in a growing market make it an attractive option for investors seeking exposure to the healthcare technology sector.
ResMed's commitment to advancing sleep and respiratory care research is evident in their support of 39 clinical research abstracts presented at major conferences. This level of involvement demonstrates the company's leadership in generating and analyzing real-world evidence, which is important for improving clinical outcomes and patient care.
The research focus on the increasing prevalence of Obstructive Sleep Apnea (OSA) is particularly noteworthy. As lifestyle factors such as obesity continue to rise globally, the incidence of OSA is likely to increase, potentially expanding ResMed's addressable market. The company's research into the economic benefits of treating OSA could be instrumental in driving greater adoption of their solutions, especially as healthcare systems worldwide focus on cost-effective interventions.
The exploration of the relationship between OSA and depression in women is an intriguing area of study. If a strong correlation is established, it could lead to increased screening and treatment of OSA in mental health settings, potentially opening new markets for ResMed's products.
From a medical perspective, ResMed's continued investment in research strengthens its position as a thought leader in sleep and respiratory care. This not only enhances the company's reputation among healthcare professionals but also provides valuable insights for product development and market expansion strategies.
However, it's important to note that while research is crucial, the translation of findings into clinical practice and market success can take time. Investors should view this research commitment as a long-term investment in ResMed's future growth and market position rather than an immediate driver of financial results.
- Year-over-year revenue grows
9% , operating profit up38% , non-GAAP operating profit up30% - Operating cash flow of
$440 million - Quarterly dividend increases
10% to$0.53 per share - Company to host an Investor Day on September 30, 2024
Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2024.
Fourth Quarter 2024 Highlights
All comparisons are to the prior year period
- Revenue increased by
9% to$1.2 billion ; up10% on a constant currency basis - Gross margin improved 350 bps to
58.5% ; non-GAAP gross margin improved 330 bps to59.1% - Income from operations increased
38% ; non-GAAP income from operations up30% - Operating cash flow of
$440 million and debt repayments of$300 million - Diluted earnings per share of
$1.98 ; non-GAAP diluted earnings per share of$2.08
Full Year 2024 Highlights
All comparisons are to the prior year period
- Revenue increased by
11% to$4.7 billion ; up11% on a constant currency basis - Gross margin improved 90 bps to
56.7% ; non-GAAP gross margin improved 120 bps to57.7% - Income from operations increased
17% ; non-GAAP income from operations up21% - Operating cash flow of
$1.4 billion and debt repayments of$0.8 billion - Diluted earnings per share of
$6.92 ; non-GAAP diluted earnings per share of$7.72
“Our fourth quarter and full-year fiscal year 2024 results demonstrate strong performance across all sectors of our business,” said Mick Farrell, Chairman & CEO of ResMed. “Ongoing patient and customer demand for our best-in-class products and software solutions is incredibly strong, driving solid growth across our devices, masks, and software businesses. The global ResMed team’s focus on operating excellence, ongoing cost discipline, and profitable growth acceleration resulted in gross margin expansion, strong operating leverage, and double-digit growth in bottom-line profitability.
“Nearly 2.5 billion suffer from major sleep health and breathing disorders. As the market leader in these significantly underpenetrated markets, we’re well-positioned as the clear leader to drive increased market penetration, demand generation, and accelerate growth for our businesses. We’re laser-focused on increasing awareness with the fast-growth population of sleep-health-interested consumers, creating virtual pathways that expand access to therapies, while offering a broad portfolio of medical device products, software solutions, and beyond, as we deliver value for all ResMed stakeholders.”
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
| Three Months Ended | |||||||||||||
| June 30, 2024 | June 30, 2023 | % Change | Constant Currency(A) | ||||||||||
| Revenue | $ | 1,223.2 | $ | 1,122.1 | 9 | % | 10 | % | |||||
| Gross margin | 58.5 | % | 55.0 | % | 6 | ||||||||
| Non-GAAP gross margin(B) | 59.1 | % | 55.8 | % | 6 | ||||||||
| Selling, general, and administrative expenses | 242.2 | 240.7 | 1 | 1 | |||||||||
| Research and development expenses | 80.9 | 78.1 | 3 | 4 | |||||||||
| Income from operations | 381.2 | 275.3 | 38 | ||||||||||
| Non-GAAP income from operations(B) | 400.5 | 307.0 | 30 | ||||||||||
| Net income | 292.2 | 229.7 | 27 | ||||||||||
| Non-GAAP net income(B) | 306.3 | 235.5 | 30 | ||||||||||
| Diluted earnings per share | $ | 1.98 | $ | 1.56 | 27 | ||||||||
| Non-GAAP diluted earnings per share(B) | $ | 2.08 | $ | 1.60 | 30 | ||||||||
| Twelve Months Ended | |||||||||||||
| June 30, 2024 | June 30, 2023 | % Change | Constant Currency(A) | ||||||||||
| Revenue | $ | 4,685.3 | $ | 4,223.0 | 11 | % | 11 | % | |||||
| Gross margin | 56.7 | % | 55.8 | % | 2 | ||||||||
| Non-GAAP gross margin(B) | 57.7 | % | 56.5 | % | 2 | ||||||||
| Selling, general, and administrative expenses | 917.1 | 874.0 | 5 | 5 | |||||||||
| Research and development expenses | 307.5 | 287.6 | 7 | 8 | |||||||||
| Income from operations | 1,319.9 | 1,131.9 | 17 | ||||||||||
| Non-GAAP income from operations(B) | 1,478.4 | 1,224.4 | 21 | ||||||||||
| Net income | 1,021.0 | 897.6 | 14 | ||||||||||
| Non-GAAP net income(B) | 1,139.3 | 949.8 | 20 | ||||||||||
| Diluted earnings per share | $ | 6.92 | $ | 6.09 | 14 | ||||||||
| Non-GAAP diluted earnings per share(B) | $ | 7.72 | $ | 6.44 | 20 | ||||||||
(A) In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Discussion of Fourth Quarter Results
All comparisons are to the prior year period unless otherwise noted
- Revenue grew by 10 percent on a constant currency basis, driven by increased demand for our sleep devices and masks portfolio, as well as strong growth across our Software as a Service business.
- Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 10 percent.
- Revenue in Europe, Asia, and other markets, excluding Software as a Service, grew by 8 percent on a constant currency basis.
- Software as a Service revenue increased by 10 percent, reflecting continued organic growth in our SaaS portfolio.
- Gross margin increased by 350 basis points mainly due to reduced freight and manufacturing cost improvements, an increase in average selling prices as well as favorable product mix. Non-GAAP gross margin increased by 330 basis points due to the same factors.
- Selling, general, and administrative expenses increased by 1 percent on a constant currency basis. SG&A expenses improved to 19.8 percent of revenue in the quarter, compared with 21.5 percent in the same period of the prior year. The modest increase in SG&A expenses reflects cost management initiatives implemented during the December quarter.
- Income from operations increased by 38 percent, and non-GAAP income from operations increased by 30 percent.
- Net income for the quarter was
$292 million and diluted earnings per share was$1.98 . Non-GAAP net income increased by 30 percent to$306 million , and non-GAAP diluted earnings per share increased by 30 percent to$2.08 , predominantly attributable to strong sales and gross margin improvement as well as modest growth in operating expenses. - Operating cash flow for the quarter was
$440 million , compared to net income in the current quarter of$292 million and non-GAAP net income of$306 million . - During the quarter, we paid
$71 million in dividends and repurchased 232,000 shares for consideration of$50 million as part of our ongoing capital management.
Other Business and Operational Highlights
- Supported the presentation of 39 clinical research abstracts at the annual American Thoracic Society (26 abstracts) and SLEEP (13 abstracts) conferences, demonstrating the breadth and depth of ResMed’s leadership in generating and analyzing real-world evidence in support of better clinical and patient outcomes. Research focused on a variety of topics including the increasing prevalence of Obstructive Sleep Apnea (OSA), the economic benefits of treating OSA, and the relationship between OSA and depression in women.
Dividend program
The ResMed board of directors today declared a quarterly cash dividend of
Webcast details
ResMed will discuss its fourth quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2024 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13747201. The telephone replay will be available until August 15, 2024.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||||||||
| Net revenue | $ | 1,223,195 | $ | 1,122,057 | $ | 4,685,297 | $ | 4,222,993 | |||||||
| Cost of sales | 499,681 | 496,276 | 1,982,769 | 1,836,935 | |||||||||||
| Amortization of acquired intangibles(1) | 7,987 | 8,395 | 32,963 | 30,396 | |||||||||||
| Masks with magnets field safety notification expenses(1) | — | — | 6,351 | — | |||||||||||
| Astral field safety notification expenses(1) | — | — | 7,911 | — | |||||||||||
| Total cost of sales | $ | 507,668 | $ | 504,671 | $ | 2,029,994 | $ | 1,867,331 | |||||||
| Gross profit | $ | 715,527 | $ | 617,386 | $ | 2,655,303 | $ | 2,355,662 | |||||||
| Selling, general, and administrative | 242,187 | 240,687 | 917,136 | 874,003 | |||||||||||
| Research and development | 80,861 | 78,144 | 307,525 | 287,642 | |||||||||||
| Amortization of acquired intangibles(1) | 11,262 | 12,319 | 46,521 | 42,020 | |||||||||||
| Restructuring expenses(1) | — | 9,177 | 64,228 | 9,177 | |||||||||||
| Acquisition related expenses(1) | — | 1,792 | — | 10,949 | |||||||||||
| Total operating expenses | $ | 334,310 | $ | 342,119 | $ | 1,335,410 | $ | 1,223,791 | |||||||
| Income from operations | $ | 381,217 | $ | 275,267 | $ | 1,319,893 | $ | 1,131,871 | |||||||
| Other income (expenses), net: | |||||||||||||||
| Interest expense, net | $ | (5,920 | ) | $ | (14,943 | ) | $ | (45,708 | ) | $ | (47,379 | ) | |||
| Gain (loss) attributable to equity method investments | 868 | (2,228 | ) | (1,848 | ) | (7,265 | ) | ||||||||
| Gain on equity investments(1) | (15,473 | ) | (1,583 | ) | (4,045 | ) | 9,922 | ||||||||
| Gain on insurance recoveries(1) | — | 20,227 | — | 20,227 | |||||||||||
| Other, net | (2,960 | ) | 61 | (3,494 | ) | (5,712 | ) | ||||||||
| Total other income (expenses), net | (23,485 | ) | 1,534 | (55,095 | ) | (30,207 | ) | ||||||||
| Income before income taxes | $ | 357,732 | $ | 276,801 | $ | 1,264,798 | $ | 1,101,664 | |||||||
| Income taxes | 65,495 | 47,137 | 243,847 | 204,108 | |||||||||||
| Net income | $ | 292,237 | $ | 229,664 | $ | 1,020,951 | $ | 897,556 | |||||||
| Basic earnings per share | $ | 1.99 | $ | 1.56 | $ | 6.94 | $ | 6.12 | |||||||
| Diluted earnings per share | $ | 1.98 | $ | 1.56 | $ | 6.92 | $ | 6.09 | |||||||
| Non-GAAP diluted earnings per share(1) | $ | 2.08 | $ | 1.60 | $ | 7.72 | $ | 6.44 | |||||||
| Basic shares outstanding | 146,915 | 147,015 | 147,021 | 146,765 | |||||||||||
| Diluted shares outstanding | 147,533 | 147,554 | 147,550 | 147,455 | |||||||||||
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
| June 30, 2024 | June 30, 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 238,361 | $ | 227,891 | |||
| Accounts receivable, net | 837,275 | 704,909 | |||||
| Inventories | 822,250 | 998,012 | |||||
| Prepayments and other current assets | 459,833 | 437,018 | |||||
| Total current assets | $ | 2,357,719 | $ | 2,367,830 | |||
| Non-current assets: | |||||||
| Property, plant, and equipment, net | $ | 548,025 | $ | 537,856 | |||
| Operating lease right-of-use assets | 151,121 | 127,955 | |||||
| Goodwill and other intangibles, net | 3,327,959 | 3,322,640 | |||||
| Deferred income taxes and other non-current assets | 487,570 | 395,427 | |||||
| Total non-current assets | $ | 4,514,675 | $ | 4,383,878 | |||
| Total assets | $ | 6,872,394 | $ | 6,751,708 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 237,728 | $ | 150,756 | |||
| Accrued expenses | 377,678 | 365,660 | |||||
| Operating lease liabilities, current | 25,278 | 21,919 | |||||
| Deferred revenue | 152,554 | 138,072 | |||||
| Income taxes payable | 107,517 | 72,224 | |||||
| Short-term debt | 9,900 | 9,902 | |||||
| Total current liabilities | $ | 910,655 | $ | 758,533 | |||
| Non-current liabilities: | |||||||
| Deferred revenue | $ | 137,343 | $ | 119,186 | |||
| Deferred income taxes | 79,339 | 90,650 | |||||
| Operating lease liabilities, non-current | 141,444 | 116,853 | |||||
| Other long-term liabilities | 42,257 | 68,166 | |||||
| Long-term debt | 697,313 | 1,431,234 | |||||
| Long-term income taxes payable | — | 37,183 | |||||
| Total non-current liabilities | $ | 1,097,696 | $ | 1,863,272 | |||
| Total liabilities | $ | 2,008,351 | $ | 2,621,805 | |||
| Stockholders’ equity | |||||||
| Common stock | $ | 588 | $ | 588 | |||
| Additional paid-in capital | 1,896,604 | 1,772,083 | |||||
| Retained earnings | 4,991,647 | 4,253,016 | |||||
| Treasury stock | (1,773,267 | ) | (1,623,256 | ) | |||
| Accumulated other comprehensive income | (251,529 | ) | (272,528 | ) | |||
| Total stockholders’ equity | $ | 4,864,043 | $ | 4,129,903 | |||
| Total liabilities and stockholders’ equity | $ | 6,872,394 | $ | 6,751,708 | |||
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income | $ | 292,237 | $ | 229,664 | $ | 1,020,951 | $ | 897,556 | |||||||
| Adjustment to reconcile net income to cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 43,677 | 46,760 | 176,870 | 165,156 | |||||||||||
| Amortization of right-of-use assets | 11,077 | 8,440 | 39,339 | 32,406 | |||||||||||
| Stock-based compensation costs | 21,392 | 19,927 | 80,184 | 71,142 | |||||||||||
| (Gain) loss attributable to equity method investments, net of dividends received | (868 | ) | 5,102 | 1,848 | 10,138 | ||||||||||
| (Gain) loss on equity investments | 15,473 | 1,584 | 4,045 | (9,922 | ) | ||||||||||
| Non-cash restructuring expenses | — | 9,177 | 33,239 | 9,177 | |||||||||||
| Gain on insurance recoveries | — | (20,227 | ) | — | (20,227 | ) | |||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivable, net | (57,523 | ) | (18,059 | ) | (134,278 | ) | (106,511 | ) | |||||||
| Inventories, net | 8,910 | 6,257 | 172,203 | (248,833 | ) | ||||||||||
| Prepaid expenses, net deferred income taxes and other current assets | (16,237 | ) | (51,518 | ) | (115,213 | ) | (138,125 | ) | |||||||
| Accounts payable, accrued expenses, income taxes payable and other | 121,975 | 330 | 122,072 | 31,342 | |||||||||||
| Net cash provided by operating activities | $ | 440,113 | $ | 237,437 | $ | 1,401,260 | $ | 693,299 | |||||||
| Cash flows from investing activities: | |||||||||||||||
| Purchases of property, plant, and equipment | (24,881 | ) | (34,449 | ) | (99,460 | ) | (119,672 | ) | |||||||
| Patent registration and acquisition costs | (1,442 | ) | (4,285 | ) | (15,396 | ) | (14,328 | ) | |||||||
| Business acquisitions, net of cash acquired | (19,697 | ) | (1,524 | ) | (133,464 | ) | (1,012,749 | ) | |||||||
| Purchases of investments | (3,073 | ) | (2,500 | ) | (12,765 | ) | (32,229 | ) | |||||||
| Proceeds from exits of investments | 750 | — | 1,000 | 3,937 | |||||||||||
| (Payments) / proceeds on maturity of foreign currency contracts | 1,833 | (3,765 | ) | (9,699 | ) | 15,196 | |||||||||
| Net cash used in investing activities | $ | (46,510 | ) | $ | (46,523 | ) | $ | (269,784 | ) | $ | (1,159,845 | ) | |||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from issuance of common stock, net | 27,696 | 23,493 | 53,094 | 49,142 | |||||||||||
| Purchases of treasury stock | (50,004 | ) | — | (150,011 | ) | — | |||||||||
| Taxes paid related to net share settlement of equity awards | (421 | ) | (334 | ) | (8,757 | ) | (30,631 | ) | |||||||
| Payments of business combination contingent consideration | — | (2,045 | ) | (1,293 | ) | (2,361 | ) | ||||||||
| Proceeds from borrowings, net of borrowing costs | — | — | 105,000 | 1,070,000 | |||||||||||
| Repayment of borrowings | (300,000 | ) | (145,000 | ) | (835,000 | ) | (405,000 | ) | |||||||
| Dividends paid | (70,553 | ) | (64,705 | ) | (282,320 | ) | (258,276 | ) | |||||||
| Net cash (used in) / provided by financing activities | $ | (393,282 | ) | $ | (188,591 | ) | $ | (1,119,287 | ) | $ | 422,874 | ||||
| Effect of exchange rate changes on cash | $ | 130 | $ | (2,326 | ) | $ | (1,719 | ) | $ | (2,147 | ) | ||||
| Net increase / (decrease) in cash and cash equivalents | 451 | (3 | ) | 10,470 | (45,819 | ) | |||||||||
| Cash and cash equivalents at beginning of period | 237,910 | 227,894 | 227,891 | 273,710 | |||||||||||
| Cash and cash equivalents at end of period | $ | 238,361 | $ | 227,891 | $ | 238,361 | $ | 227,891 | |||||||
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and restructuring expense related to cost of sales and are reconciled below:
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||||||||
| Revenue | $ | 1,223,195 | $ | 1,122,057 | $ | 4,685,297 | $ | 4,222,993 | |||||||
| GAAP cost of sales | $ | 507,668 | $ | 504,671 | $ | 2,029,994 | $ | 1,867,331 | |||||||
| Less:Amortization of acquired intangibles(A) | (7,987 | ) | (8,395 | ) | (32,963 | ) | (30,396 | ) | |||||||
| Less: Masks with magnets field safety notification expenses(A) | — | — | (6,351 | ) | — | ||||||||||
| Less: Astral field safety notification expenses(A) | — | — | (7,911 | ) | — | ||||||||||
| Non-GAAP cost of sales | $ | 499,681 | $ | 496,276 | $ | 1,982,769 | $ | 1,836,935 | |||||||
| GAAP gross profit | $ | 715,527 | $ | 617,386 | $ | 2,655,303 | $ | 2,355,662 | |||||||
| GAAP gross margin | 58.5 | % | 55.0 | % | 56.7 | % | 55.8 | % | |||||||
| Non-GAAP gross profit | $ | 723,514 | $ | 625,781 | $ | 2,702,528 | $ | 2,386,058 | |||||||
| Non-GAAP gross margin | 59.1 | % | 55.8 | % | 57.7 | % | 56.5 | % | |||||||
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:
| Three Months Ended | Twelve Months Ended | ||||||||||
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||||
| GAAP income from operations | $ | 381,217 | $ | 275,267 | $ | 1,319,893 | $ | 1,131,871 | |||
| Amortization of acquired intangibles—cost of sales(A) | 7,987 | 8,395 | 32,963 | 30,396 | |||||||
| Amortization of acquired intangibles—operating expenses(A) | 11,262 | 12,319 | 46,521 | 42,020 | |||||||
| Restructuring(A) | — | 9,177 | 64,228 | 9,177 | |||||||
| Masks with magnets field safety notification expenses(A) | — | — | 6,351 | — | |||||||
| Astral field safety notification expenses(A) | — | — | 7,911 | — | |||||||
| Acquisition-related expenses(A) | — | 1,792 | 483 | 10,949 | |||||||
| Non-GAAP income from operations | $ | 400,466 | $ | 306,950 | $ | 1,478,350 | $ | 1,224,413 | |||
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| June 30, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||||||||
| GAAP net income | $ | 292,237 | $ | 229,664 | $ | 1,020,951 | $ | 897,556 | |||||||
| Amortization of acquired intangibles—cost of sales(A) | 7,987 | 8,395 | 32,963 | 30,396 | |||||||||||
| Amortization of acquired intangibles—operating expenses(A) | 11,262 | 12,319 | 46,521 | 42,020 | |||||||||||
| Restructuring expenses(A) | — | 9,177 | 64,228 | 9,177 | |||||||||||
| Masks with magnets field safety notification expenses(A) | — | — | 6,351 | — | |||||||||||
| Astral field safety notification expenses(A) | — | — | 7,911 | — | |||||||||||
| Acquisition-related expenses(A) | — | 1,792 | 483 | 10,949 | |||||||||||
| Gain on insurance recoveries(A) | — | (20,227 | ) | — | (20,227 | ) | |||||||||
| Income tax effect on non-GAAP adjustments(A) | (5,145 | ) | (5,631 | ) | (40,114 | ) | (20,114 | ) | |||||||
| Non-GAAP net income(A) | $ | 306,341 | $ | 235,489 | $ | 1,139,294 | $ | 949,757 | |||||||
| GAAP diluted shares outstanding | 147,533 | 147,554 | 147,550 | 147,455 | |||||||||||
| GAAP diluted earnings per share | $ | 1.98 | $ | 1.56 | $ | 6.92 | $ | 6.09 | |||||||
| Non-GAAP diluted earnings per share(A) | $ | 2.08 | $ | 1.60 | $ | 7.72 | $ | 6.44 | |||||||
(A) ResMed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, field safety notification expenses, acquisition-related expenses, gain on insurance recoveries, and associated tax effects from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)
| Three Months Ended | |||||||||||
| June 30, 2024 | (A) | June 30, 2023 | (A) | % Change | Constant Currency(B) | ||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 406.2 | $ | 387.2 | 5 | % | |||||
| Masks and other | 321.2 | 273.7 | 17 | ||||||||
| Total U.S., Canada and Latin America | $ | 727.4 | $ | 660.9 | 10 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 228.8 | $ | 215.2 | 6 | % | 8 | % | |||
| Masks and other | 115.0 | 107.4 | 7 | 9 | |||||||
| Total Combined Europe, Asia and other markets | $ | 343.9 | $ | 322.6 | 7 | 8 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 635.1 | $ | 602.4 | 5 | % | 6 | % | |||
| Total Masks and other | 436.2 | 381.0 | 14 | 15 | |||||||
| Total Sleep and Respiratory Care | $ | 1,071.3 | $ | 983.5 | 9 | 9 | |||||
| Software as a Service | 151.9 | 138.6 | 10 | 10 | |||||||
| Total | $ | 1,223.2 | $ | 1,122.1 | 9 | 10 | |||||
| Twelve Months Ended | |||||||||||
| June 30, 2024 | (A) | June 30, 2023 | (A) | % Change | Constant Currency(B) | ||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 1,522.8 | $ | 1,444.4 | 5 | % | |||||
| Masks and other | 1,199.8 | 1,039.0 | 15 | ||||||||
| Total U.S., Canada and Latin America | $ | 2,722.6 | $ | 2,483.4 | 10 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 921.3 | $ | 826.3 | 11 | % | 10 | % | |||
| Masks and other | 457.4 | 415.3 | 10 | 8 | |||||||
| Total Combined Europe, Asia and other markets | $ | 1,378.6 | $ | 1,241.6 | 11 | 10 | |||||
| Global revenue | |||||||||||
| Total Devices | $ | 2,444.0 | $ | 2,270.7 | 8 | % | 7 | % | |||
| Total Masks and other | 1,657.2 | 1,454.3 | 14 | 13 | |||||||
| Total Sleep and Respiratory Care | $ | 4,101.2 | $ | 3,725.0 | 10 | 10 | |||||
| Software as a Service | 584.1 | 498.0 | 17 | 17 | |||||||
| Total | $ | 4,685.3 | $ | 4,223.0 | 11 | 11 | |||||
(A) Totals and subtotals may not add due to rounding.
(B) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
| For investors | For media |
| +1 858-836-5000 | +1 619-510-1281 |
| investorrelations@resmed.com | news@resmed.com |
FAQ
What was ResMed's (RMD) revenue growth in Q4 2024?
How much did ResMed's (RMD) operating profit increase in Q4 2024?
What was ResMed's (RMD) diluted earnings per share for Q4 2024?
Did ResMed (RMD) increase its dividend in Q4 2024?
What was ResMed's (RMD) full-year revenue for fiscal year 2024?
